The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).
 
Victoria K Woodcock
No Relationships to Disclose
 
Karin Purshouse
No Relationships to Disclose
 
Chrissie Butcher
No Relationships to Disclose
 
Caroline Haddon
No Relationships to Disclose
 
Gillian Verrall
No Relationships to Disclose
 
Leena Elhussein
No Relationships to Disclose
 
Mariolina Salio
No Relationships to Disclose
 
Mark R. Middleton
Honoraria - Amgen; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; CytomX Therapeutics; Merck; Newlink Genetics; Novartis; RigonTEC
Research Funding - Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); RigonTEC (Inst); Roche (Inst); TC Biopharm (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Merck
 
Vincenzo Cerundolo
No Relationships to Disclose
 
Jeremy Crew
No Relationships to Disclose
 
Andrew Protheroe
Honoraria - Astellas Oncology; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; MSD; Pfizer; Roche
Speakers' Bureau - Ipsen
Research Funding - AstraZeneca (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Bayer; Ipsen